Procaps Group S.A.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jose Antonio Toledo Vieira
- Full Time Employees
- 5,500
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 9 Rue de Bitbourg Luxembourg City Luxembourg 1273
- IPO Date
- Dec 9, 2019
- CIK
- 0001863362
- Website
- procapsgroup.com
- Similar Companies
- Business
- Procaps Group S.A. (NASDAQ: PROC) develops, manufactures, and markets a broad portfolio of pharmaceutical and nutraceutical solutions, including over-the-counter (OTC) medications, prescription drugs (Rx), nutritional supplements, high-potency clinical solutions, and hospital supplies; the company operates through key segments such as NextGel for softgel manufacturing and distribution, Procaps Colombia for prescription and OTC products in Colombia, CAN for Northern Central America (El Salvador, Guatemala, Nicaragua, Honduras), CASAND for Southern Central America (Panama, Costa Rica) and North Andes (Ecuador, Peru, Bolivia), and Diabetrics for diabetes management tools. Founded in 1977 in Barranquilla, Colombia, by Ruben Minski, Procaps Group maintains headquarters in Luxembourg with recent relocation of strategic leadership to Bogotá, Colombia, and employs nearly 5,000 people across 13 countries primarily in the Americas while reaching more than 50 markets on five continents; it features state-of-the-art facilities including the first FDA-approved plant in Latin America for Rx products, U.S.-based softgel production in West Palm Beach, Florida, and a gummies facility under construction in Miramar, Florida. The company targets pharmaceutical research, hospitals, consumer healthcare, and chronic disease management sectors with branded products in areas like pain relief, feminine care, skin care, and innovative delivery technologies such as soft gelatin capsules protected by over 30 patents. Recent developments include a Secured Convertible Note Subscription Agreement for up to $40 million with Hoche Partners Pharma Holdings (initial $20 million at 8.50% interest), forbearance extensions on $209 million debt to January 2025, $5 million investment from controlling shareholders, Board restructurings with new committees and directors post-2024 Annual General Meeting, leadership transitions including Ruben Minski's resignation as Executive Chairman (effective June 30, 2024) and José Minski's appointment as Chairman, Patricio Vargas shift to Chief Optimization Officer, sale of non-core assets, headquarters move to Bogotá with new investor leadership, and ongoing financial restatements alongside governance enhancements.
ProCook Group (LON:PROC) Trading Up 5.9% – Should You Buy?
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Procaps Group Receives Delisting Notice From Nasdaq
Procaps Group Receives Additional Delinquency Letter
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
Procaps Group Announces Financing, Shareholders Agreement and Board Updates
Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing
Procaps Issues Shareholder Letter Update
Procaps Issues Shareholder Letter Update
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024
Procaps Issues Shareholder Letter
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Procaps Group Delays Filing of Annual Report on Form 20-F
Procaps Group Delays Filing of Annual Report on Form 20-F
Procaps Group – Notice to Shareholders
Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates
Procaps Group Reports Third Quarter 2023 Results